HRT for Depression: What the Evidence Actually Shows — and Who It May Help

The HRT Index Editorial TeamIndependent women's health research

Last reviewed:September 2, 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: September 2, 2026 · Last verified: September 2, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Before you make an HRT decision about mood

Separate urgent mental-health care, depression treatment, and menopause symptom care before choosing an online HRT route.

Use Find My HRT Path

If you are thinking about harming yourself, or you do not feel able to stay safe right now: call or text 988 in the United States, or use the 988 Lifeline chat. If the danger is immediate, call 911 or go to the nearest emergency department. Please do that before you finish this page. We will still be here.

HRT for depression is not FDA-approved and should not replace standard depression care. But small trials found real benefit in some perimenopausal women: one reported remission in 68% on a 100-mcg estradiol patch versus 20% on placebo. A separate postmenopausal trial using the same nominal patch dose found no clinically significant antidepressant benefit.

Last verified: September 2, 2026 · By The HRT Index Editorial Team · Editorial research — not medical advice, and not medically reviewed by a clinician

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

That gap is the whole story. A 100-mcg estradiol patch produced a striking result in one small perimenopause trial and no clinically significant antidepressant effect in a separate postmenopause trial. Then a later placebo-controlled perimenopause trial failed to confirm a clear benefit.

So the honest answer is not “HRT works for depression” or “HRT never works for depression.” The useful answer is narrower: menopause stage, the timing of your mood change, your other menopause symptoms, and whether you meet criteria for a depressive disorder all change the next conversation.

Is this page for you?

This page is for women deciding whether HRT belongs in a depression conversation—not for anyone trying to self-prescribe or replace urgent mental-health care. The most relevant pattern is mood change arriving during perimenopause with cycle disruption, hot flashes, night sweats, or broken sleep; several red-flag situations need another starting point.

This page is most useful if:

You are still having periods, even irregular ones, or you are in early postmenopause.
Your mood changed around the same time as hot flashes, night sweats, cycle disruption, or broken sleep.
You are trying to understand whether menopause treatment belongs in the conversation without pretending it replaces depression care.
You want the positive trials and the failed trials in the same place.

Do not use this page as your only next step if:

You have thoughts of harming yourself or cannot stay safe. Call or text 988 in the United States; call 911 for immediate danger.
You have depressed mood or loss of interest most of the day, nearly every day, for at least two weeks, and it is interfering with daily life. You need a depression evaluation whether or not menopause is involved.
You have a history of mania, hypomania, or bipolar disorder.
Your mood became sharply worse after starting, stopping, or changing a hormone or psychiatric medication. Contact the prescriber who changed it.
You are years past menopause and are considering systemic HRT only as a depression treatment. That is where the estradiol evidence is weakest.

That last group is not a lost cause. It means a different treatment lane is more likely to give you a real answer — and chasing hormones alone could cost you months.

Your situation changes the route

The right online HRT provider is not the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer cannot resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care is not the right starting point — before your first consult.

→ Use Find My HRT Path — about 90 seconds, no email required

Does HRT help with depression?

Sometimes — but that answer breaks apart the moment you ask which women, which outcome, and which stage. Small trials found antidepressant effects from transdermal estradiol in some perimenopausal women with diagnosed depressive disorders. Other randomized trials failed, including a postmenopause trial and a 2021 perimenopause trial. Major guidelines therefore do not treat HRT as routine depression therapy.

Here is the thing most pages get wrong.

“Menopause depression” is not one neat diagnosis. Menopause-related depressive symptoms and a depressive disorder can wear the same coat. They can also exist at the same time.

Hot flashes, night sweats, sleep loss, fatigue, poor concentration, irritability, low libido, and low mood can cluster during the menopause transition. Depression can also cause sleep disruption, fatigue, concentration trouble, loss of interest, and impaired functioning. A symptom list alone cannot tell you which process is driving what.

The distinction matters because the recommendations are not the same.

NICE says to consider HRT for depressive symptoms that do not meet criteria for a depression diagnosis when they began around the same time as other menopause symptoms.
The European Society of Endocrinology recommends against routinely using menopausal hormone therapy to treat clinical depression in perimenopause or menopause.
FIGO's 2026 best-practice recommendations say perimenopausal women with menopause symptoms including mild depression may benefit from MHT, while major depressive disorder and suicidal ideation need urgent multidisciplinary psychiatric care.
The Menopause Society/National Network of Depression Centers guidance treats antidepressants and psychotherapy as front-line therapies for perimenopausal depression, while acknowledging evidence that estrogen can have antidepressant effects in some perimenopausal women and is not FDA-approved for that use.

Those positions are not fighting. They are answering different versions of the question.

The four guidelines, side by side

These four documents are not answering one identical question. NICE addresses depressive symptoms below a depression diagnosis; FIGO gives a both/and route for mild symptoms and urgent multidisciplinary care for major depression; the European guideline rejects routine MHT for clinical depression; the 2018 expert guidance keeps depression treatments front-line while acknowledging a perimenopause signal.

Source	The patient question it answers	What it says	The boundary that matters
NICE NG23, recommendation 1.5.21	Depressive symptoms beginning with other menopause symptoms, below the threshold for a depression diagnosis	Consider HRT	This recommendation is not for a diagnosed depressive disorder
European Society of Endocrinology guideline, recommendation 3.14	Clinical depression in perimenopause or menopause	Do not routinely use menopausal hormone therapy to treat it	Evidence certainty is rated very low; the recommendation still does not make HRT first-line depression care
FIGO best-practice recommendations, 2026	Mental health during perimenopause and menopause	Individualize care; MHT may help perimenopausal women with menopause symptoms including mild depression, while major depressive disorder and suicidal ideation require urgent multidisciplinary psychiatric care	Current global guidance supports a both/and route rather than using hormones to downgrade major depression
Maki et al., Menopause Society/NNDC guidance	Perimenopausal depression	Antidepressants and psychotherapy are front-line; estrogen has evidence of antidepressant effects in some perimenopausal women, especially with vasomotor symptoms	Estrogen is not FDA-approved for perimenopausal depression; evidence for estrogen plus progestogen is sparse and inconclusive

Read those rows again. The first question is menopause-related depressive symptoms below a depression diagnosis. The second is clinical depression. The third asks how to manage perimenopausal depression without pretending one treatment has to erase every other one.

If two clinicians have sounded as though they were giving opposite answers, this may be why. One may have been answering “Could treating menopause symptoms help this woman feel better?” while the other was answering “Should hormone therapy replace established treatment for a depressive disorder?”

Those are not the same question.

Low mood is not a home diagnosis — and neither is major depression

The National Institute of Mental Health describes major depression as depressed mood or loss of interest most of the time for at least two weeks, with interference in daily activities. That is a screening boundary, not permission to diagnose yourself from a webpage.

Depression can fluctuate. Perimenopausal mood symptoms can be persistent. A woman can have both. The calendar alone cannot diagnose either one.

What the timeline can do is make the first appointment more useful. Bring:

When your cycle changed.
When hot flashes, night sweats, or sleep disruption began.
When low mood, loss of interest, anxiety, irritability, or hopelessness began.
Whether the mood change is constant, cyclical, or tied to medication changes.
Whether you have had depression, postpartum depression, severe premenstrual mood symptoms, mania, or hypomania before.
What has changed in your ability to work, care for yourself, or feel interested in your life.

That pattern does more work than the sentence “I think it is hormonal.”

What does the research say about HRT for depression?

The research contains a real signal and a real failure problem. Two small early placebo-controlled perimenopause trials reported large response or remission differences. A postmenopause trial found no clinically significant antidepressant benefit, and a larger 2021 perimenopause trial did not show a clear estradiol advantage over placebo. A prevention trial answers a different question again.

This is the table we built because quoting the win without the loss is not an evidence review. It is a trailer.

The Stage × Design × Outcome Trial Ledger

The ledger separates six studies that are often collapsed into one promise. Two early placebo-controlled perimenopause trials were positive, one later placebo-controlled perimenopause trial was negative, one open-label stage comparison favored perimenopause, one postmenopause trial failed, and one prevention study enrolled women who were not depressed at baseline.

Study	Population and design	Treatment	Time	Result	What the result can actually support
Schmidt 2000	34 women with perimenopause-related depression; randomized, double-blind, placebo-controlled first phase	Transdermal 17β-estradiol	3 weeks before crossover	Full or partial response in 80% on estradiol versus 22% on placebo	A strong preliminary signal in a very small sample
Soares 2001	50 perimenopausal women with DSM-IV depressive disorders; randomized, double-blind, placebo-controlled	Transdermal 17β-estradiol, 100 mcg/day	12 weeks	Remission in 68% (17/25) on estradiol versus 20% (5/25) on placebo	The strongest single treatment result in this literature — still only 50 participants
Cohen 2003	22 depressed peri- and postmenopausal women; open-label, no placebo group; 20 completed	Transdermal estradiol, 100 mcg/day	4 weeks	Eight completers remitted; six were perimenopausal and two were postmenopausal	A stage signal, not a randomized comparison and not proof of a peri-versus-post treatment difference
Morrison 2004	57 postmenopausal women with mild-to-moderate depression; randomized and placebo-controlled	Transdermal estradiol, 0.1 mg/day	8 weeks	A clinically significant antidepressant effect was excluded	Strong evidence against using this regimen as an antidepressant in this postmenopausal sample
Gordon 2018	172 initially euthymic perimenopausal and early-postmenopausal women; randomized, placebo-controlled prevention trial	Transdermal estradiol 0.1 mg/day plus intermittent oral micronized progesterone	12 months	17.3% crossed a clinically significant depressive-symptom threshold at least once versus 32.3% on placebo	A prevention signal in women who were not depressed at baseline — not a treatment-remission trial
Schmidt 2021	66 women with perimenopause-related depression randomized; 62 analyzed across four arms	Transdermal estradiol 100 mcg/day, raloxifene, Rimostil, or placebo	8 weeks	No treatment-group effect on CES-D or BDI; estradiol's HRSD difference from placebo was not statistically significant in the pairwise comparison	A later placebo-controlled failure that stops the early positive trials from being treated as settled fact

A few things become obvious when all six studies sit together.

First: the 68% versus 20% result is real. So is the 80% versus 22% preliminary response result. The page should not bury them merely because they are inconvenient to a cautious conclusion.

Second: the failures are real too. Morrison found no clinically significant antidepressant effect in postmenopausal women. Schmidt 2021 failed to show a clear estradiol advantage over placebo on its main depression scales in women with perimenopause-related depression.

Third: the most dramatic stage contrast does not come from the same randomized study. Soares and Morrison were separate trials with different participants and protocols, although both used a nominal transdermal estradiol dose of 100 mcg/day. That cross-trial contrast is useful. It is not the same thing as randomizing perimenopausal and postmenopausal women head-to-head.

Fourth: Gordon 2018 is often placed in a treatment pile where it does not belong. Those women were not depressed when the trial began. Crossing a screening threshold during follow-up is not the same outcome as remission from a diagnosed depressive disorder.

That is the ledger. Two early wins. One open-label stage signal. One postmenopause failure. One prevention signal. One later perimenopause failure.

Anyone giving you only the first half is not giving you the evidence. Anyone giving you only the failures is not giving it to you either.

What did “remission” mean in the best trial?

It did not mean every symptom vanished forever. It meant a participant's depression rating fell below that study's remission cutoff at the measured endpoint.

That matters because “68% remission” can sound like a permanent cure when it was a result inside a 12-week, 50-person trial. It is still striking. It is not a guarantee, and it is not an FDA-approved claim.

The 2015 review said the quiet part out loud

A review titled So Much Promise and So Few Answers examined 24 studies and found only five randomized trials in women who were actually depressed. Only two samples were exclusively perimenopausal. The authors found some evidence for estradiol in perimenopausal depression, little support in postmenopausal depression, and little evidence that estradiol lifted mood in women without depression.

That was 2015. The 2021 failure and the two 2026 meta-analyses added evidence, but they did not turn this into a clean antidepressant standard.

Why the two 2026 meta-analyses look as though they disagree

These 2026 reviews look contradictory only if their populations, comparators, and analysis rules are hidden. One asked a narrow perimenopause depression question and found a small average effect; the other pooled much broader psychological outcomes and reported a larger estimate that did not survive its stricter trial-sequential check for depression.

Question	Li et al., 2026	Shou et al., 2026
What population and question?	HRT for depressive symptoms in perimenopausal women	Hormone therapy and phytoestrogens across multiple psychological outcomes in broad peri- and postmenopausal populations
Search end date	December 23, 2025	March 1, 2026
Evidence included	12 randomized trials	51 hormone-therapy RCTs with 41,821 participants, plus 16 phytoestrogen RCTs
Depression estimate	HRT versus placebo: SMD −0.23 (95% CI −0.43 to −0.03)	44 hormone-therapy depression comparisons: SMD 0.73 (95% CI 0.66 to 0.79), I² 62.87%
Route finding	No clear difference by route	Effects varied across formulations, stages, durations, and outcomes
Authors' limiting conclusion	Effect was small; certainty was limited	Conventional depression result did not pass trial-sequential-analysis correction; pooled findings were too heterogeneous for direct real-world application

Do not compare −0.23 with +0.73 as though they sit on one simple scoreboard. Standardized mean differences can point in opposite numeric directions depending on how scales and comparison groups are coded. The analyses also pooled different women, regimens, outcomes, and study sets.

The useful agreement is harder to put in an ad, which is why you rarely see it:

The depression-specific perimenopause review found a small average effect with limited certainty.
The broader review found a larger pooled depression estimate, but its own statistical stress test did not establish that hormone-therapy depression result as conclusive.
Neither analysis turns HRT into an FDA-approved or guideline-standard treatment for clinical depression.

So if someone tells you the science is now definitive in either direction, they have read a headline instead of the evidence stack.

The honest weaknesses, because you should hear them from us

We would rather you find these here than later and wonder what else we skipped.

The most exciting treatment trials were tiny. Thirty-four women. Fifty women. Those are not numbers that justify a universal promise.
The randomized findings are mixed even inside perimenopause. The 2021 estradiol trial did not reproduce a clear placebo advantage.
Different studies measured different things. Response, remission, rating-scale change, and prevention of crossing a symptom threshold are not interchangeable.
Estrogen-only evidence cannot answer every combined-HRT question. Women with a uterus generally need endometrial protection when using systemic estrogen, and the mood evidence for estrogen plus progestogen is thinner.
Some mood benefit may be indirect. If HRT stops night sweats and restores sleep, mood may improve even when the hormone is not acting like a conventional antidepressant.
The broad meta-analyses are heterogeneous. Different stages, formulations, durations, baseline symptoms, and scales can make one pooled number look cleaner than the studies really are.

That is not a reason to throw the signal away. It is a reason to use it for the question it can answer:

Does my menopause stage and symptom pattern make a menopause treatment conversation reasonable alongside — not instead of — proper depression care?

Is HRT FDA-approved to treat depression?

No. The FDA has not approved estrogen, progesterone, or any menopausal hormone product to treat depression. FDA-approved menopausal hormone products have product-specific indications such as vasomotor symptoms, vulvar or vaginal symptoms, and — for some products — prevention of postmenopausal osteoporosis. A clinician may prescribe an approved drug off-label, but the depression claim is not FDA-approved.

We read the current Prometrium prescribing information because this is where wording matters.

The current brand label is revision 02/2026. DailyMed marks the label Updated July 23, 2026 and lists the current version as published July 27, 2026. It lists two indications:

Prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving conjugated estrogens.
Treatment of secondary amenorrhea.

Depression is not one of them.

“Not FDA-approved for depression” does not mean no clinician can ever discuss off-label use. It means the FDA has not determined that a menopausal hormone product is safe and effective for the depression indication under an approved application. That distinction belongs on the page, especially when marketing copy tries to turn a small trial into an approved use.

What menopausal hormone therapy is FDA-approved to treat

Depending on the exact product and label, FDA-approved hormone therapies may be indicated for:

Moderate-to-severe vasomotor symptoms, including hot flashes and night sweats.
Vulvar or vaginal symptoms associated with menopause, including dryness or pain with sexual activity.
Prevention of postmenopausal osteoporosis for certain products.

If your mood dropped while night sweats began wrecking your sleep, a clinician may still consider hormone therapy for those menopause symptoms if it is appropriate for you. That is not a back door to calling HRT a depression drug. It is treating an approved menopause indication while tracking mood as a separate outcome.

What changed in 2025 and 2026 — and what did not

If a page says the FDA removed every menopause hormone boxed warning from every product, that page has outrun the facts.

On November 10, 2025, the FDA announced that it was initiating label changes to remove certain boxed-warning statements related to cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products.
Drug companies still had to submit product-specific labeling changes for FDA review.
On February 12, 2026, the FDA announced the first batch of six products with approved labeling changes: Prometrium; Divigel, Cenestin, and Enjuvia; Estring; and Bijuva.
The FDA's current updated-product page still identifies those six products.
The boxed warning concerning endometrial cancer remains for systemic estrogen-alone products.
Other warnings and contraindications remain in product labeling. A boxed-warning change is not a declaration that hormone therapy is risk-free.

This matters because stale fear copy is still everywhere. It also matters because “the warnings are gone” is now becoming its own form of misinformation.

The correct sentence is: the FDA approved specified boxed-warning changes for an initial six products in February 2026, while product-specific updates continue.

About compounded hormones and mood claims

Straight talk: compounded hormone products are not FDA-approved. They do not have an FDA-reviewed prescribing label or an FDA-approved depression indication. The FDA says it does not have evidence that compounded products marketed as “bioidentical” are safer or more effective than FDA-approved hormone therapy.

A compounded product can be appropriate for a specific patient when an FDA-approved option cannot meet a documented clinical need. That is different from marketing it as a superior mood treatment.

If a clinic markets a compounded cream, pellet, or troche as though it is proven to treat depression, that is a claim you should make them prove. “Customized,” “natural,” and “bioidentical” do not turn a compounded product into an FDA-reviewed one.

When mood is the thing you are tracking, the difference matters more than usual. An FDA-approved product gives you a label with indications, contraindications, warnings, adverse-event tables, and postmarketing information you can inspect. A compounded preparation does not come with an FDA-reviewed equivalent.

Should I take HRT or an antidepressant?

This is usually not a clean either/or. For a diagnosed depressive disorder, antidepressants and psychotherapy remain established treatments, and current European guidance says not to routinely use menopausal hormone therapy as the treatment for clinical depression. If you also have treatable menopause symptoms, those symptoms can be assessed and treated on their own merits — sometimes alongside depression care.

You may have been handed this as a referendum on whether your symptoms are “real.” It is not.

Being offered an antidepressant does not mean anyone has proved your hormones are irrelevant. Being offered HRT for hot flashes does not mean anyone has proved your depression is hormonal. Both treatments can be legitimate, and both can be wrong for a particular person.

The question is which problem each treatment is being asked to solve.

Why an antidepressant may be offered first

There are three honest reasons:

Your symptoms may meet criteria for a depressive disorder. Persistent low mood or loss of interest, impaired functioning, suicidal thoughts, major appetite or sleep changes, guilt, hopelessness, and concentration trouble deserve a depression assessment whether menopause is present or not.
The symptom overlap is real. Fatigue, broken sleep, poor concentration, low libido, and irritability can appear in both depression and the menopause transition.
Antidepressants can serve more than one purpose. Some antidepressants are also used as nonhormonal options for vasomotor symptoms. A prescription does not prove anyone thinks this is “all in your head.”

Here is the permission-giving part: you do not have to reject one lane to ask about the other.

It does not have to be one or the other

If an antidepressant or therapy has helped but hot flashes, night sweats, or sleep disruption remain brutal, those menopause symptoms still deserve treatment. If HRT improves the physical symptoms but your low mood and loss of interest do not move, that mood question still deserves established depression care.

The catch is coordination.

Two prescribers changing two medication systems while nobody owns the follow-up is a bad setup when mood is the outcome. Before adding or changing anything, establish:

Who manages the antidepressant or other psychiatric medication.
Who manages the hormone regimen.
Who should be contacted if mood worsens.
When the first follow-up will happen.
Which symptoms will be tracked separately.

Do not stop an antidepressant abruptly or change a hormone dose on your own. The fact that a treatment may be wrong does not make an unsupervised stop safe.

The part we would rather not tell you

We are going to be blunt because you can smell a sales pitch, and we would rather keep your trust than your click.

Hormone therapy is not reliably better than an antidepressant for depression. It failed in the Morrison postmenopause trial. A later placebo-controlled perimenopause trial did not show a clear estradiol advantage. The European Society of Endocrinology recommends against routinely using menopausal hormone therapy to treat clinical depression. The depression-specific 2026 meta-analysis found only a small average effect with limited certainty.

If you meet criteria for clinical depression and spend the next six months cycling through hormone regimens while avoiding effective depression treatment, those are six months you do not get back. We are not willing to be the page that helped that happen.

But the perimenopausal signal still deserves your attention. Not because it proves HRT is an antidepressant for everyone. Because it shows that a defined group of women had a meaningful response in controlled trials, and current guidance allows menopause treatment to be considered when depressive symptoms arrived with other menopause symptoms and do not meet criteria for a depression diagnosis.

The better question is not “Which side am I on?”

It is:

What am I asking the hormone therapy to treat, what am I asking depression care to treat, and who is tracking whether either one is working?

Which situation are you in?

Most searches for HRT and depression collapse several different clinical situations into one phrase. The strongest reason to discuss HRT is a menopause-symptom pattern — especially perimenopausal mood change with hot flashes, night sweats, or disrupted sleep — in someone who is otherwise an appropriate candidate. Crisis symptoms, clinical depression, bipolar history, and medication-triggered worsening need different starting points.

This is the part to save.

Perimenopause is the transition around the final menstrual period. Periods often become irregular, and symptoms may begin years before the last one. In everyday clinical use, postmenopause begins after 12 consecutive months without a period when no other cause explains the amenorrhea.

The nine-situation next-step matrix

This matrix is a routing tool, not a self-diagnosis. It separates immediate danger, likely depressive-disorder care, the perimenopause pattern most similar to positive estradiol trials, medication-related worsening, established postmenopause, vaginal-estrogen confusion, and bipolar history. Its output is the next conversation to arrange—not permission to start or change hormones.

Your situation	Where HRT may fit	What should not wait	Best first conversation
1. You are thinking about harming yourself or cannot stay safe	Nothing on this page should delay help	Immediate crisis support	Call or text 988 in the US; call 911 for immediate danger
2. Low mood or loss of interest is present most of the day, nearly every day, for at least two weeks, or you cannot function normally	Menopause symptoms may still be assessed, but HRT is not the only evaluation you need	A depression assessment	Primary care or a mental health clinician promptly
3. Your mood changed during perimenopause with irregular cycles, hot flashes, night sweats, or broken sleep — without crisis signs	This is the clearest situation for discussing HRT as part of a menopause-symptom plan if it is otherwise appropriate	Do not ignore persistent or impairing depression symptoms	A menopause-informed clinician, with a defined mood follow-up
4. Your mood became sharply worse after starting, stopping, or changing hormones	The regimen and timing need review; do not assume the answer is simply “more” or “less” hormone	Contact the prescribing clinician	The prescriber who changed the regimen
5. You are stable on an antidepressant or in therapy, but vasomotor symptoms and sleep disruption remain severe	HRT may be considered for the menopause indications if appropriate; mood improvement would be tracked separately	Keep depression treatment stable unless its prescriber changes it	Coordinated menopause and mental-health care
6. You have low mood but no cycle change, hot flashes, night sweats, or other menopause pattern	HRT is not a default depression treatment	Evaluate other causes and depression if symptoms persist or impair functioning	Primary care or mental health
7. You are years postmenopausal and considering systemic HRT only for depression	This is where estradiol treatment evidence is least supportive	Established depression assessment and treatment	Mental health or primary care first; menopause care separately for other symptoms
8. You hope vaginal estrogen will improve mood	Low-dose vaginal estrogen treats genitourinary symptoms, not depression	Evaluate the mood question separately	One conversation for GSM; another for mood
9. You have a history of mania, hypomania, or bipolar disorder	Hormone symptoms can still be assessed, but medication changes need psychiatric context	Do not start changing psychiatric or hormone treatment without coordinated oversight	A mental health clinician familiar with your history, with menopause care coordinated around it

Read this if you landed in row 1 or 2

You are not unusual, and you have not failed at anything.

If you cannot stay safe, the right next move is a person, not another study. The US 988 Suicide & Crisis Lifeline is free, confidential, and available 24/7 by call or text. In immediate danger, call 911.

If you are in row 2, getting a depression evaluation does not close the hormone door. It stops one theory from delaying care while both questions are sorted out.

Read this if you landed in row 4

A mood crash after a medication change is information. Write down:

The date the medication or dose changed.
When the mood shift began.
Whether it is constant or appears on specific days of a cycle.
Any new agitation, sleeplessness, panic, impulsivity, or suicidal thoughts.
Every hormone, psychiatric medication, supplement, and dose you are taking.

Then contact the prescriber. Do not wait three months for a routine review if the change is sharp, frightening, or disabling.

Your four-question appointment script

You do not need to deliver a lecture. You need four answers and one clear request.

What stage am I in? “My last normal period was , and my cycle has changed like this: .”
What arrived together? “My mood changed around ; hot flashes/night sweats/sleep disruption began around .”
What is my psychiatric history? “I have/have not had major depression, postpartum depression, severe premenstrual mood symptoms, mania, hypomania, or psychiatric medication before.”
What am I taking and do I have a uterus? “I currently take ___, and I do/do not have a uterus.”

Then say:

“I want two questions assessed separately: whether I need treatment for depression, and whether treating my menopause symptoms is appropriate. If we try a hormone regimen, who will track my mood, what would count as worsening, and when will we review it?”

That is a better appointment than “Can I have HRT for depression?” It does not make the answer smaller. It makes it harder to dismiss.

→ Match your stage, symptoms, risk flags, insurance route, and state with Find My HRT Path

Can HRT make depression worse?

Mood can worsen after a hormone regimen starts or changes, and that timing deserves prompt review. The current Prometrium label reports depression in 19% of women taking cyclic Prometrium plus conjugated estrogens versus 12% on placebo in one trial. That table does not prove causation and cannot identify which component produced the difference. It is still information worth seeing.

This is the section that might talk you out of something. We are publishing it anyway.

What the current Prometrium label actually reports

On September 2, 2026, we opened the current DailyMed prescribing information for Prometrium (progesterone) capsules. The label is revision 02/2026; DailyMed marks it Updated July 23, 2026 and lists the current version as published July 27, 2026.

Table 7 reports adverse reactions from a multicenter, randomized, double-blind, placebo-controlled trial in 875 postmenopausal women over three years. The two columns reproduced below compare women taking cyclic Prometrium 200 mg for 12 days per month plus conjugated estrogens 0.625 mg (n=178) with women taking placebo (n=174).

Adverse reaction	Prometrium + conjugated estrogens	Placebo
Headache	31%	27%
Breast tenderness	27%	6%
Joint pain	20%	29%
Depression	19%	12%
Dizziness	15%	9%
Abdominal bloating	12%	5%
Hot flashes	11%	35%
Worry	8%	4%

That 19% is uncomfortable. We did not enjoy publishing it.

Now read it correctly.

What the 19% versus 12% figure proves — and what it does not

The same table can be abused in opposite directions. It neither proves progesterone caused depression nor makes the signal irrelevant. The active arm combined progesterone with estrogen, the placebo group also reported depression, and the table reports observed adverse reactions. Its value is in deciding what to monitor and when to contact the prescriber.

The table supports this statement	The table does not support this statement
More women in the combination-treatment arm reported depression than women in the placebo arm in this trial	Prometrium alone caused depression in 19% of users
The observed difference was seven percentage points	Every seven-point difference was caused by progesterone
Mood belongs in the pre-treatment and follow-up conversation	The same rate applies to every progesterone, dose, route, population, or modern HRT regimen
An FDA-reviewed label exposes an adverse-event table readers can inspect	A compounded product with no FDA-reviewed label must therefore be safer

Notice the placebo column. Twelve percent of women taking placebo also reported depression. Notice the joint-pain and hot-flash rows, where placebo was worse. An adverse-reaction table records what happened in a particular trial; it does not automatically establish that the drug caused every event.

The combination arm also included conjugated estrogens. The table cannot isolate progesterone as the cause of the depression difference.

The correct damaging admission is still damaging:

In this trial, depression was reported more often in the Prometrium-plus-estrogen arm than in the placebo arm.

That belongs in your decision. It does not belong in a panic headline claiming progesterone causes suicidal depression.

What the current label says about monitoring

The current brand Prometrium label's dedicated PRECAUTIONS section covers fluid retention, dizziness and drowsiness, patient information, drug-laboratory-test interactions, carcinogenesis and fertility, pregnancy, nursing, pediatric use, and geriatric use. It does not contain a separate precaution instructing clinicians to monitor people with a prior history of clinical depression.

That absence is an inspectable label fact. It is not evidence that mood monitoring is unnecessary.

Your history still belongs in the conversation because:

Depression appeared as an adverse reaction in the combination-treatment trial.
Mood can change after medications are started or adjusted.
The label's postmarketing section lists suicidal ideation among voluntarily reported nervous-system events.

The postmarketing section, handled carefully

The current label lists suicidal ideation in its Postmarketing Experience section.

That section is not a controlled trial. The label explains that postmarketing reports are voluntary, come from a population of uncertain size, cannot be used to estimate frequency reliably, and do not establish a causal relationship to the drug.

So this is not evidence that Prometrium causes suicidal ideation.

It is evidence that the event has been reported and that a woman with current or past depression deserves a named follow-up plan — not a package arriving with nobody clearly responsible for what happens next.

If suicidal thoughts are happening now, call or text 988 in the United States. If you are in immediate danger, call 911.

If your mood worsens after starting or changing HRT

Do not quietly run an experiment on yourself.

Immediate danger or inability to stay safe: call or text 988; call 911 for immediate danger.
Sharp mood decline, new agitation, panic, severe insomnia, impulsivity, or frightening thoughts after a change: contact the prescriber promptly; same-day contact is appropriate when safety or functioning is deteriorating.
Milder but repeatable worsening: log the timing and contact the prescriber before changing the dose, route, or schedule yourself.
Cyclical worsening during a progestogen phase: record the exact days and regimen. The pattern may help the prescriber evaluate formulation, schedule, dose, or another cause.
No improvement despite controlled hot flashes: separate the mood outcome from the menopause outcome and reopen the depression question.

A prescriber may consider changing the formulation, route, dose, schedule, or treatment plan. That is an option to discuss, not a promise that every mood problem can be fixed by swapping progesterone.

Why an FDA-approved product can tell you an uncomfortable number

Here is the argument, and it is the reason we spent time reading the label.

The 19% figure is uncomfortable. But it exists in an FDA-reviewed label attached to a defined regimen, comparator, population, and trial.

A compounded cream has no equivalent FDA-reviewed adverse-event table. Not because the absence proves it is safer. Because the compounded product was not approved through the same product-specific process and does not carry an FDA-reviewed label.

When mood is the outcome you care about, an uncomfortable number you can interrogate beats an empty space dressed up as reassurance.

How long does HRT take to help mood?

The trials measured mood at endpoints ranging from three to twelve weeks, but they do not establish one guaranteed onset time. The European Society of Endocrinology recommends reevaluating menopausal hormone therapy after three months for treatment effect, adverse effects, and tolerability. Worsening mood should be reviewed sooner; a routine three-month checkpoint is not a reason to wait through danger.

Put the review date in your calendar the day treatment begins.

Not because three months is magic. Because a treatment without a defined checkpoint can turn into six months of “maybe give it longer,” followed by another dose change, followed by no clear answer.

What the trial timelines actually were

Schmidt 2000 measured the first randomized phase at three weeks.
Cohen 2003 used a four-week open-label course.
Morrison 2004 tested postmenopausal depression over eight weeks.
Schmidt 2021 ran for eight weeks.
Soares 2001 measured the main treatment result at twelve weeks.
Gordon 2018 followed prevention of depressive symptoms over twelve months.

Those are study endpoints, not a personalized countdown clock.

Track two outcomes, not one foggy feeling

Use the same short tracker before and after a treatment change so memory does not decide the result. It separates mood from hot flashes, sleep, cycle timing, and progestogen exposure; records function rather than feelings alone; and creates an explicit escalation trigger when safety changes. It is a conversation aid, not a diagnostic instrument.

Track	A simple measure	Why it matters
Mood	0–10 morning mood plus one sentence	Shows direction without requiring a diary novel
Interest	One activity you normally care about: did you want to do it?	Loss of interest is not the same as irritability or fatigue
Function	Work, childcare, meals, hygiene, leaving home	Improvement should show up somewhere in life, not only in a vague impression
Vasomotor symptoms	Number of hot flashes/night sweats	Separates the approved menopause outcome from the mood outcome
Sleep	Awakenings and approximate hours slept	Shows whether mood change may be arriving through better sleep
Medication timing	Estrogen/progestogen days and any psychiatric-medication changes	Makes a repeatable pattern visible
Safety	New suicidal thoughts, severe agitation, impulsivity, or inability to function	These trigger contact now, not at the routine review

Keep it small enough to use. One minute a day beats a perfect tracker abandoned after four days.

What “it worked” should mean at the review

Ask four separate questions:

Did hot flashes or night sweats improve?
Did sleep improve?
Did mood, interest, or daily function improve?
Did any new adverse effect appear?

A hormone regimen can succeed on the first two and fail on the third. That is not contradictory. It means the treatment did its menopause job while the mood problem still needs another lane.

In the Soares trial, 68% met the study's remission threshold — which also means 32% did not. Even the best result in this evidence base left about one in three women without remission.

That is the realistic expectation: a meaningful possibility in a selected perimenopausal group, not a promise.

When to change direction

At the planned review, one of four things should happen:

Clear benefit, acceptable adverse effects: continue the shared decision about the regimen and future review.
Partial benefit: identify which outcome changed and which did not before adjusting anything.
No benefit: reassess the indication, diagnosis, formulation, adherence, and other causes rather than escalating by reflex.
Mood worsening or intolerable effects: review sooner and change course with the prescriber.

If vasomotor symptoms are controlled but mood is unchanged, the hormones may have completed their actual job. Your next move is not automatically a higher dose. It is a depression assessment or treatment review.

Which type of HRT has the best evidence for mood?

The classic positive depression trials used transdermal 17β-estradiol, but that does not prove a patch is the best antidepressant form of HRT. A 2021 trial of a 100-mcg estradiol patch did not clearly beat placebo, and the 2026 depression-specific meta-analysis found no confirmed route advantage. Product choice should follow the approved menopause indication, risk profile, uterus status, and tolerability.

Let us be precise because a lot of pages are not.

What is true: the best-known positive treatment trials used transdermal estradiol. Soares used 100 mcg/day. Schmidt 2000 used a transdermal regimen. Cohen used 100 mcg/day in an open-label study.

What is also true: Morrison used the same nominal 100-mcg/day dose in postmenopausal women and found no clinically significant antidepressant effect. Schmidt 2021 also used 100 mcg/day in perimenopause and did not show a clear advantage over placebo.

What is not true: “The patch is proven to be the best HRT for depression.”

The 2026 depression-specific meta-analysis did not find a clear difference by route, and no definitive head-to-head trial establishes a mood winner.

A patch may still be chosen for reasons that are not about mood

The European Society of Endocrinology recommends that route choice account for individual characteristics, comorbidities, preference, availability, and cost. For a woman with a previous venous thromboembolism in whom MHT is still indicated after individual risk-benefit assessment, the guideline recommends low-dose transdermal estrogen.

That is a route-and-risk argument. It is not evidence that a patch treats depression better.

If you have a uterus, the progestogen question matters

Systemic estrogen in a woman with a uterus generally requires endometrial protection with a progestogen or another appropriate regimen. That is not an optional mood hack. It is part of using systemic estrogen safely.

The mood evidence becomes harder here because many of the classic estradiol treatment trials do not answer every real-world combined-regimen question. The Menopause Society/NNDC guidance describes evidence for estrogen plus progestogen in perimenopausal depression as sparse and inconclusive.

So ask the actual regimen question:

Which estrogen product and route?
Which progestogen and schedule?
What is the reason for each component?
What mood pattern should trigger contact?
When is the review?

“Bioidentical” is not an answer to any of those.

Vaginal estrogen is a different treatment lane

Low-dose vaginal estrogen is used for genitourinary syndrome of menopause — symptoms such as vaginal dryness, tissue discomfort, and pain with sex. The Menopause Society notes that very little enters blood circulation with low-dose vaginal therapy.

That is why it should not be sold to you as a systemic mood treatment.

You may need vaginal estrogen and a separate plan for depression or systemic menopause symptoms. That is not duplication. It is two treatments doing two different jobs.

What about testosterone?

Honest answer: not for this claim.

There is no FDA-approved testosterone product for women in the United States. FDA-approved testosterone products are approved for men with low testosterone tied to an associated medical condition. Use in women is off-label.

Testosterone is also a Schedule III controlled substance in the United States. It requires a prescription and controlled-substance compliance; no online page should make obtaining it sound casual or automatic.

The sole evidence-based indication identified by international expert guidance for testosterone therapy in women is hypoactive sexual desire disorder in appropriately assessed postmenopausal women — not depression. The FDA has identified ongoing evidence gaps around testosterone use in menopausal women, including mood and long-term safety.

A clinic presenting testosterone as the missing depression cure is moving faster than the evidence and the approvals.

Where should I get assessed for HRT and depression?

Start where both safety and continuity are real. Online menopause care can assess menopause symptoms and, where appropriate, prescribe hormone therapy; it should not present HRT as a substitute for evaluation and treatment of clinical depression. Crisis symptoms, major functional decline, bipolar history, or abrupt medication-related worsening need a mental-health or in-person clinical lane first.

Before we tell you what good care looks like, here is who should not begin with a generic online HRT checkout.

Online menopause care is not the right first door if:

You have thoughts of harming yourself or cannot stay safe. Call or text 988 in the United States; call 911 for immediate danger.
Your symptoms suggest a major depressive episode or you cannot function. Seek primary-care or mental-health assessment promptly.
You have a history of mania, hypomania, or bipolar disorder. Psychiatric context matters before medication changes.
Your mood deteriorated sharply after a medication change. Contact the prescriber who changed it.
You need diagnosis or management of a psychiatric disorder or psychiatric medication. A menopause service that does not provide that care cannot substitute for it.
Your situation requires examination, urgent testing, complex risk evaluation, or care the online service cannot provide. A responsible service should refer out rather than force a fit.

We would rather lose you here than route you wrong.

What to look for under The HRT Index Verification Standard

The five pillars become concrete safety checks on this page. The table below tells you what to verify before intake or payment: who assesses depression risk, who owns follow-up, which product and approval status are being offered, what the full care path costs, and what happens when online care is not enough.

Pillar	What good care looks like for this exact question	Red flag
Clinical legitimacy	A licensed clinician assesses contraindications, psychiatric history, current medications, and when referral is needed	A symptom quiz is treated as a diagnosis or prescription guarantee
Care quality	A named follow-up path exists, mood worsening has an escalation route, and treatment is reviewed around three months or sooner when needed	A package ships with no clear clinician ownership of follow-up
Medication fit	FDA-approved and compounded options are clearly separated; systemic versus local treatment and uterus status are handled correctly	Compounded products are described as equivalent, safer, more natural, or proven for mood
Price transparency	Consult, follow-up, medication, lab, and membership costs are disclosed before payment or clearly labeled as confirmed at intake/checkout	A teaser price hides required costs
Access	State availability, insurance or cash-pay lane, communication method, refill process, cancellation terms, and referral limits are visible	The service appears available until late intake, or cannot explain what happens when online care is not appropriate

One criterion matters more here than on a simple hot-flash page:

Will the service say no?

A service that refers someone with crisis symptoms, active major depression, mania history, or an unsuitable medical profile is doing assessment. A service that never finds a person it cannot treat is doing acquisition.

The right division of labor

A workable plan may look like this:

A primary-care or mental-health clinician diagnoses and treats the depressive disorder.
A menopause clinician assesses vasomotor, sleep, bleeding, genitourinary, or other menopause symptoms.
One clinician is identified as the first contact if mood worsens.
Medication changes are shared between prescribers.
Mood and menopause outcomes are reviewed separately.

That is less emotionally satisfying than finding one person who promises to fix everything. It is also much safer than asking one hormone prescription to carry every problem on its back.

A note about online routing and privacy

Find My HRT Path is an educational routing tool, not a clinic, diagnosis, or prescription service. The live tool says it takes about 90 seconds, requires no email, stores answers only in temporary memory in the open tab, and uses a state suggestion that can be edited. A licensed clinician makes all treatment decisions.

Because menopause-routing answers can be sensitive health information, read the site's Consumer Health Data Privacy Policy before using any health tool. Do not put personal medical details into a general contact form.

→ See which care route fits — and when online care is not the right starting point

What are the most common questions about HRT for depression?

Most follow-up questions fall into six buckets: combining HRT with antidepressants, progesterone effects, compounded products, testing, prevention, and what to do after symptoms worsen. The answers keep the same boundary: HRT may treat menopause symptoms and sometimes improve mood, but it is not an FDA-approved stand-alone treatment for clinical depression.

Can HRT replace my antidepressant?

Not as a general rule, and never by stopping an antidepressant on your own. Current European guidance recommends against routinely using menopausal hormone therapy to treat clinical depression. HRT may still be assessed for menopause symptoms, and any mood effect should be tracked separately with the clinician managing your depression care.

Can I take HRT and an antidepressant at the same time?

They can be used together in some patients, but the answer depends on the exact products, your diagnoses, contraindications, and other medications. Have one prescriber review the complete medication list and establish who owns follow-up before anything changes.

Does estrogen affect serotonin?

Estrogen interacts with neurotransmitter systems, including serotonin signaling, and that is one proposed mechanism for mood effects. Mechanism is not proof of clinical benefit. The mixed trial results — positive in some perimenopausal samples and negative in others — are exactly why biology alone cannot settle the treatment question.

Can perimenopause cause anxiety as well as depression symptoms?

Anxiety, irritability, sleep disruption, and low mood can all occur during the menopause transition. They can also reflect anxiety disorders, depression, thyroid disease, medication effects, substance use, sleep apnea, trauma, or other conditions. Timing and symptom pattern help, but persistent or impairing symptoms still need assessment.

Will my mood return to normal after menopause?

No page can promise that. Some fluctuation-related symptoms ease after the transition, while depression or anxiety may continue for reasons that are not solved by stable hormone levels. Do not use the possibility of later improvement as a reason to white-knuckle through treatable symptoms now.

Can progesterone cause depression?

The current Prometrium label reports depression in 19% of women receiving cyclic Prometrium plus conjugated estrogens versus 12% on placebo in one trial. That observed difference does not prove progesterone caused the events, and the trial cannot isolate progesterone from the estrogen component. A repeatable mood decline after a regimen starts or changes still deserves prompt review.

Is compounded or “bioidentical” HRT better for mood?

No reliable evidence establishes compounded HRT as better for mood. Compounded products are not FDA-approved and do not have FDA-reviewed labels or approved depression indications. FDA says it does not have evidence that compounded products marketed as bioidentical are safer or more effective than FDA-approved hormone therapy.

Do I need a blood test to prove my low mood is hormonal?

No single blood test can prove that menopause caused low mood. Current European guidance recommends against routine biochemical testing to diagnose perimenopause or menopause in women over 45 with typical symptoms. Testing can still be appropriate in specific situations, including younger age, atypical symptoms, or evaluation for another condition.

Does HRT prevent depression?

One randomized trial found that initially euthymic perimenopausal and early-postmenopausal women receiving transdermal estradiol plus intermittent micronized progesterone were less likely to cross a clinically significant depressive-symptom threshold over 12 months than women receiving placebo: 17.3% versus 32.3%. That is one prevention trial, not an FDA-approved prevention indication or a general guideline recommendation.

What if my clinician will not discuss HRT with me?

Bring a specific, bounded request: “My mood and these menopause symptoms began around the same time. Can we assess whether I meet criteria for depression and whether treatment for my menopause symptoms is appropriate? If we try HRT, what outcome are we treating and when will we review it?” A clear question is harder to dismiss than asking for a hormone as a cure-all.

How do I tell perimenopause from “just a hard year”?

Look at timing and company, not one dramatic day. Cycle change, hot flashes, night sweats, and new sleep disruption can support a menopause pattern, while persistent loss of interest, hopelessness, and functional decline support a depression assessment. Life stress and perimenopause can also happen together. This is not a test you have to pass before asking for help.

Does HRT help brain fog?

Some women report cognitive symptoms improving as sleep and vasomotor symptoms improve, but hormone therapy should not be used to prevent or treat dementia. Read the broader mood, anxiety, and cognition guide and sleep guide for those separate questions.

Will vaginal estrogen help depression?

No evidence supports low-dose vaginal estrogen as a depression treatment. It is a local treatment for genitourinary symptoms and produces little systemic exposure. See the vaginal estrogen guide for what it is designed to treat.

What are the nonhormonal options for menopause symptoms?

Options depend on the symptom and your health history. They can include FDA-approved nonhormonal medicines for vasomotor symptoms, certain antidepressants used for hot flashes, behavioral approaches, and targeted treatment for sleep or genitourinary symptoms. See nonhormonal menopause options and the broader HRT benefits and risks guide.

What is the bottom line on HRT for depression?

HRT has a genuine but narrow depression signal in perimenopause, not a universal antidepressant effect. One small trial found 68% remission versus 20% on placebo; another later perimenopause trial and a postmenopause trial were negative. No product is FDA-approved for depression, and diagnosed depression still needs established care.

Hormone therapy has genuine randomized evidence for depression in some perimenopausal women. The strongest single treatment trial reported 68% remission versus 20% on placebo.

It also has genuine failures.

A postmenopause trial using the same nominal 100-mcg daily patch dose found no clinically significant antidepressant benefit. A later placebo-controlled perimenopause trial did not show a clear estradiol advantage on its main depression scales. The newest depression-specific meta-analysis found only a small average effect with limited certainty. The European Society of Endocrinology recommends against routinely using menopausal hormone therapy to treat clinical depression.

No menopausal hormone product is FDA-approved to treat depression.

That does not make the early results fake. It makes the question narrower.

The useful question was never “Is HRT the cure for depression?”

It is:

Does my mood change sit inside a treatable menopause-symptom pattern, do I also need depression care, and who will track both without letting one delay the other?

Getting that right is worth more than any hormone.

Still not sure which HRT program is right for you? Take our free matching quiz — about 90 seconds.

Answer a few private questions about your stage, symptoms, risk flags, insurance route, and state. Find My HRT Path will show which online care routes fit your situation — and, just as importantly, flag when online care is not the right starting point.

→ Start Find My HRT Path

What did we actually verify?

This final audit used current primary sources, not summaries: four guidelines or best-practice documents, six key studies, both 2026 meta-analyses, the current Prometrium label, FDA relabeling pages, compounded-drug guidance, testosterone scheduling, crisis guidance, and live site/tool pages. Claims that did not survive those checks were removed or corrected.

On September 2, 2026, The HRT Index Editorial Team:

Read NICE NG23 recommendation 1.5.21 on depressive symptoms beginning with other menopause symptoms and not meeting criteria for a depression diagnosis.
Read recommendation 3.14 and the evidence grade in the 2025 European Society of Endocrinology clinical practice guideline, plus its recommendations on three-month review, uterus status, route selection, and biochemical testing.
Read the 2026 FIGO best-practice recommendations on mild depressive symptoms, MHT when indicated, and urgent multidisciplinary care for major depressive disorder or suicidal ideation.
Reviewed the Menopause Society/National Network of Depression Centers guidance for perimenopausal depression.
Checked the primary records for the six studies in the Stage × Design × Outcome Trial Ledger, including the 2021 placebo-controlled failure omitted from the draft.
Checked the 2026 Li depression-specific meta-analysis and the 2026 Shou broad psychological-outcomes meta-analysis, including their study counts, effect estimates, heterogeneity, and limiting conclusions.
Opened the current DailyMed label for Prometrium, revision 02/2026, DailyMed update date July 23, 2026, and current-version publication date July 27, 2026, and checked the indications, Table 7 adverse-event rates, PRECAUTIONS section, and Postmarketing Experience section.
Checked the FDA's November 10, 2025 labeling announcement, February 12, 2026 first-batch approval, and current list of six products with updated prescribing information.
Checked current FDA language on compounded hormone products and the approved uses of menopausal hormone therapy.
Checked FDA and DEA sources for testosterone approval status and Schedule III control, plus international consensus guidance on the evidence-based indication in women.
Checked the live Find My HRT Path page for its current duration, no-email statement, temporary-memory disclosure, and clinician-decision disclaimer.
Confirmed that this informational page contains no provider-specific price, insurance, state-availability, laboratory-inclusion, or cancellation claim that could go stale; those variables are routed to the current tool instead of frozen into the article.

We did not take, test, receive, or accept a hormone product or clinical service for this page. This is editorial research, not medical advice, and it was not medically reviewed by a clinician. Where a claim could not be verified against a current primary or authoritative source, it was removed rather than rounded into certainty.

Primary and authoritative sources

Affiliate disclosure: The HRT Index may earn a commission when a reader later chooses an eligible provider through Find My HRT Path or another clearly disclosed link. This page does not recommend a named provider or link directly to one. Commercial relationships do not change the evidence, disqualification rules, or editorial conclusions above.

Choose the care route that matches the problem.

Compare the best online HRT providers, read the broader HRT benefits and risks guide, review nonhormonal options, or use Find My HRT Path to identify when online care is not the right starting point.

Keep reading: